Capital Group Private Client Services, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Capital Group Private Client Services, Inc.

$9.6 Billion
Q2 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $48,123 - $50,560	332 Added 0.49%	68,570 $10.4 Million
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $26,854 - $47,154	-323 Reduced 0.47%	68,238 $9.94 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $134,517 - $174,648	1,222 Added 1.81%	68,561 $8.13 Million
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $100,926 - $150,261	-1,012 Reduced 1.48%	67,339 $9.28 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $6.76 Million - $9.49 Million	68,351 New	68,351 $9.5 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.

Account